Abstract: Endocannabinoids are lipid transmitters binding and activating the cannabinoid receptors. Both cannabinoid receptors and endocannabinoids, such as 2-arachidonoylglycerol and anandamide, have been shown to control numerous physiological and pathological processes, including in the central nervous system. Thus regulating endocannabinoid levels in-vivo represents an interesting therapeutic perspective in several CNS-related diseases. To date four enzymes -Fatty Acid Amide Hydrolase (FAAH), N-Acylethanolamine-hydrolyzing Acid Amidase (NAAA), Monoacylglycerol Lipase (MAGL), / -Hydrolase Domain 6 (ABHD6) -were shown to control endocannabinoid levels in tissues or in intact cells. While the searches for NAAA and ABHD6 inhibitors are still in their beginning, a growing number of selective and potent inhibitors are now available to inhibit FAAH and MAGL activities. Here, based on the literature and patent literature, we review the compounds of the different chemical families that have been developed to inhibit these enzymes, with a special emphasis on FAAH and MAGL inhibitors.
I. INTRODUCTION
The effects of cannabinoids (from natural, synthetic and endogenous origin) are mainly mediated by two G proteincoupled receptors, the cannabinoid receptors CB 1 and CB 2 . These two receptors are activated by endogenous bioactive lipids named endocannabinoids, which are produced in an activity-dependent manner (i.e. following cell stimulation) from phospholipid precursors present in the cell membranes. So far, two types of endocannabinoids, based on an arachidonic acid moiety, have been fully characterized. Indeed, Narachidonoylethanolamine (anandamide, AEA) is a member of the large family of N-acylethanolamines, whereas 2-arachidonoylglycerol (2-AG) is an acylglycerol. The activity of these lipid mediators at the cannabinoid receptors is terminated essentially following their hydrolysis by several lipases [1] . Initially, Fatty Acid Amide Hydrolase (FAAH) [2] and Monoacylglycerol Lipase (MAGL) [3, 4] , were described as the main enzymes regulating the activity of AEA and 2-AG, respectively. More recently, additional endocannabinoid-degrading enzymes were also shown to have key roles in the endocannabinoid system. Thus, a second FAAHrelated mechanism was recently described for essentially regulating oleamide. [5] Although it shares only 20 % homology with FAAH, this novel enzyme, only found in humans, was called FAAH-2. Two serine hydrolases, / -hydrolase 6 (ABHD6) and / -hydrolase 12 (ABHD12) [6] , were also recently discovered and described as complementary 2-AG-degrading enzymes in the brain [7] . Interestingly, MAGL, ABHD6 and ABHD12 are present in different subcellular locations suggesting distinct roles in controlling 2-AG activities. In addition, another enzyme, called NAcylethanolamine-hydrolyzing Acid Amidase (NAAA), was found to regulate the levels of N-acylethanolamines [8] .
Because the activation of the cannabinoid receptors results in multiple beneficial effects, numerous CB 1 and CB 2 agonists are being described since the characterization of 9 -THC structure and of its activity at cannabinoid receptors. However direct and constant activation of the receptors resulting from this strategy presents several drawbacks, including receptor desensitization, and numerous CNS-related side effects for the CB 1 receptor agonists. Conversely, increasing selectively the levels of an endocannabinoid is expected to result in a subset of the effects induced by the agonist but with more limited side effects [9] . Therefore there is a strong rationale for the preparation of potent and selective inhibitors of endocannabinoid degradation.
Thus, following a brief summary of the enzymes' characteristics, we will review the different classes of inhibitors described in the patent literature. The main focus will be on the compounds able to inhibit FAAH and MAGL since those are the primary enzymes controlling the endocannabinoid levels. However, we will also briefly describe the novel inhibitors developed to block the activity of NAAA.
II. FATTY ACID AMIDE HYDROLASE

II.1. Pharmacology of FAAH Inhibition or why Inhibiting FAAH Activity?
FAAH is a membrane-bound serine hydrolase which belongs to a distinct class of enzymes characterized by the amidase signature (AS). It possesses an atypical catalytic triad consisting in Ser-Ser-Lys (instead of the classical SerHis-Asp) which confers to FAAH the ability to hydrolyse amide bonds of various endogenous bioactive lipids [10, 11] .
Essentially known for being the main anandamidedegrading enzyme [12] , FAAH also hydrolyses and thus regulates the endogenous levels of other bioactive lipids (Fig. (1) ). Indeed, several N-acylethanolamines (NAEs) -including N-palmitoylethanolamine (PEA), which does not activate CB receptors but induces anti-inflammatory responses via the PPAR receptors, and the satiating agent Noleoylethanol-amine (OEA) -also undergo a FAAHdependent catabolism [13, 14] . Furthermore, the levels of other classes of amide-derived lipids, like the N-acyl taurines (NATs), which activate transient receptor potential (TRP) ions channels [15] , and fatty acid primary amides (FAPAs) such as the sleep-inducing lipid oleamide [12, 16, 17] , are also regulated by FAAH. Interestingly, while the levels of these mediators are increased upon FAAH inhibition the levels of two other bioactive lipids, N-arachidonoyldopamine (a TRPV1 agonist) [18] and N-arachidonoylglycine (the putative GPR18 receptor endogenous agonist) [19] , are decreased following FAAH inhibition.
Considering all its different substrates, FAAH inhibition will result in numerous effects, with several of them not mediated by anandamide or by cannabinoid receptors. These non-CB1 and non-CB2 effects can be mediated by G protein-coupled receptors (e.g. GPR18, GPR119), ion channels (e.g. TRPV1) or nuclear receptors (e.g. PPAR) [20, 21] . To date, only the consequences of increasing the levels of the Nacylethanolamines are relatively well characterized both in cells and in-vivo. Anandamide was shown to be involved in number of physiological processes [22] [23] [24] [25] , including appetite regulation [26] , pain [27, 28] and inflammation, but also various CNS and psychiatric disorders [29] , with anxiety and depressive disorders being the most studied. Concerning other substrates, oleamide was shown to be involved in sleep induction [30, 31] , PEA is widely described as analgesic and anti-inflammatory molecule [27, 28, 32] and OEA as satiating factor and as analgesic [33] . OEA regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha [34] . Today, FAAH inhibition is generally considered as a sound therapeutic strategy in the treatment of pain and inflammation [20, [35] [36] [37] [38] [39] as well as anxiety and depression [40] [41] [42] .
II.2. FAAH, Structure and Function
Soon after the discovery of FAAH, X-ray crystallographic studies were performed to further understand its mode of action, but also to improve the research and the development of its inhibitors. Thus the rat isoform (rFAAH) was crystallised in presence of methylarachidonoylfluorophosphonate (MAFP), an irreversible and non selective inhibitor, and the structure was solved with a 2.8 Å resolution [43] , This three dimensional structure revealed the presence of several domains implicated in distinct functions. i) A large domain composed by hydrophobic and basic residues covers the active site and allows the enzyme to anchor to the membrane. ii) Near this hydrophobic plateau, lies a channel responsible for the entry of the substrate. Commonly called the membrane access channel (MAC), this cavity allows a direct access for the lipid substrate from the membrane to the active site. iii) Close to the active site, a hydrophobic cavity is present. This acyl-chain binding pocket (ABP) interacts with the side-chain of the substrate. iv) Finally, the cytosolic port (CP) was found to interact with the polar head of the substrate and is connected with the cytosol. Moreover, the active site is able to accommodate a water molecule to hydrolyse the acyl-enzyme complex. As a result, the hydrophobic moiety and the hydrophilic one are released towards the MAC and CP, respectively. (For complete reviews, see [44, 45] ) Further helping the drug development of FAAH inhibitors, an engineered "humanised" rat FAAH (h/rFAAH) [46] was produced and successively co-crystallised with three compounds representative of the major FAAH inhibitors classes [47] [48] [49] [50] . This constitutes an interesting tool, as a large number of FAAH inhibitors present differences in activity depending on the origin of the enzyme, that is mouse FAAH (mFAAH) or human FAAH (hFAAH). An alternative strategy was to develop an homology model of hFAAH based on the reported X-ray structure of rat FAAH (rFAAH) [51] . This model was validated by docking the selective inhibitor PF-750 resulting in similar interactions to those found in the co-crystal structure of PF-750 into h/rFAAH.
A large number of FAAH inhibitors have been described over the years, starting from natural substrates analogues to well-adapted traditional types of serine hydrolase inhibitors [52] [53] [54] [55] . Indeed, a wide variety of electrophilic functions has been used to target the enzyme's active site, generating large sets of structure-activity relationships aiming at improving, not only the potency, but also the selectivity of the inhibitors. Among the numerous templates described in the patent literature (Fig. (2) ), three main chemical families have been extensively studied. Below, we will review them in their order of development, starting from the -keto heterocycles [56] , then the carbamate-based inhibitors [57] and finally, the urea-derived inhibitors [58] .
II.3. FAAH Inhibitors
II.3.1. -keto Heterocycle-based FAAH Inhibitors
Activated ketones were disclosed very early in the development of FAAH inhibitors. Disclosed for inhibiting serine proteases [59, 60] , a first series was described by Dale Boger's group, who generated a series of arachidonoyl-and oleoyl-based -keto heterocycles [56] . The inhibition is based on the attack by FAAH's active serine on the electrophilic carbonyl of the inhibitor. The resulting reversible tetrahedral intermediate was recently observed in OL-135 -h/rFAAH co-crystals [48] . After studying a large range of heterocycles, -keto oxazoles and -keto oxazolopyridines were identified as the most efficacious moieties. Therefore, Boger's group refined its inhibitors and reported more potent heterocyclic inhibitors exemplified with OL-135 ( Fig. (3) , 1, IC 50 = 2.1 nM and > 100 M on mFAAH and on mMAGL, respectively), a potent and highly selective pharmacological tool commonly used and based on the pyridyl oxazole template.
From this study, an optimal C6 linker length with a phenyl end-group was chosen to replace the fatty acid chain. Beside the acyl chain, the authors also explored the impact of the heterocycle nature. Thereby, analogues were synthesised, based on 2-keto-1,3,4-oxadiazole scaffold with a subnanomolar activity (2, Fig. (3) , K i = 290 pM on rFAAH) [61] and more recently, 2-keto-1,2,4-oxadiazole scaffold (7, K i = 920 pM and 340 pM on hFAAH and rFAAH, respectively) [62]. Similarly to the C6 alkylphenyl chain, the H-bond acceptor pyridine group appeared to be responsible for the higher potency. Boger's group also investigated the substitution of either the pyridine or oxazole ring [63, 64] . Again highly potent inhibitors were obtained featuring subnanomolar activities (Fig. (3) , 3, K i = 200 pM and 2 nM on hFAAH and rFAAH, respectively; 4, K i = 900 pM on hFAAH). Focusing on the lipophilic portion that binds the ACB pocket, a series of bioisosteres was synthesized. For instance, equal activity to the C6 alkylphenyl chain was found for the C2 alkylbiphenyl chain, resulting in the inhibitor 5 (Fig. (3) , K i = 400 pM and 500 pM, on hFAAH and rFAAH, respectively) [65] . Finally, the same authors also studied the substitution of the phenyl ring at the end of the acyl side-chain, resulting in inhibitors such as 6 (Fig. (3) , K i = 400 pM on rFAAH) [66] .
Meanwhile, another study on -keto heterocycles was undertaken by the researchers of Janssen Pharmaceuticals. Based on the structure of OL-135 (1, Fig. (3) ), including the oxazole ring, they oriented their efforts toward the insertion of a piperidinyl scaffold which allows for a wide diversity of substitutions. They published two patents containing SAR studies, and exemplified here with compounds 8 (Fig. (4) , 400 pM and 4.7 nM on hFAAH and rFAAH, respectively) [67] and 9 ( Fig. (4) , Ki = 2 nM and 2 nM on hFAAH and rFAAH, respectively) [68] .
II.3.2. Carbamate-based FAAH Inhibitors
Carbamate-based FAAH inhibitors were inspired by the structures of previously reported inhibitors of serine hydrolases. This function is usually used to inhibit serine proteases in an irreversible manner. Indeed, the tetrahedral intermediate evolves towards a stable acyl-enzyme complex. This mechanism of action was put forth, first by MS analyses [69] and then by X-ray structures [50] , in studies involving URB597 (or KDS-4103, 10, Fig. (5) ) the lead compound of this class of inhibitors [70, 71] . URB597 is largely used as pharmacological tool, both in-vitro and in-vivo (IC 50 = 4.6 nM on rFAAH). In addition, analogues of 10 were synthesized in order to increase their stability towards oxidative metabolism. Indeed, hydroxylation of the C4 position was observed following in-vivo administration of 10. Thereby, this position was blocked by adding various substituents, like the gem-dimethyl found in 11 ( Fig. (5) ) [72] , allowing a significant reduction of anandamide hydrolysis (50 % of control, at 30 nM).
Additional series of analogues were also synthesized, including compound 12 (Fig. (5) , IC 50 < 0.1 M) [73] . This compound is interesting as it exhibits a good oral bioavailability (C max in plasma 2-fold higher compared to 10) and a low CNS uptake (C max in brain 10-fold lower compared to 10) which may thus allow to target selectively FAAH in the periphery while not affecting FAAH activity in the CNS. This feature may be useful to treat pain and inflammation disorders by acting at peripheral sites, without inducing potential CNS (side)effects. Another carbamate derivative, compound 13 ( Fig. (5) ), IC 50 < 0.1 M) [74] , also possesses a good oral bioavailability and its administration results in enhanced OEA and PEA levels in blood (7.55 and 8.85 ng/mL compared to 4.18 and 4.17 ng/mL for OEA and PEA, respectively). The same authors described some other inhibitors but neither their potency nor in-vivo activity were disclosed [75, 76] . Piomelli and co-workers also developed new KDS-4103-based inhibitors with the aim to reduce its activity towards liver carboxylesterases. It is indeed known that 10 (URB597, Fig. (5) ), while being quite selective, has several off-targets [77, 78] , including carboxylesterases, which could prevent its further development. Thus, URB694 (14, [79] , both possessing electron-donating substituents on the phenyl ring that reduce the electrophilicity of the carbonyl, were described. This decreased electrophilicity resulted in more selective compounds that retained their good activity against FAAH in-vitro and in-vivo [80] . Therefore, novel URB694-based inhibitors could soon be developed with improved selectivity for FAAH. Note that recently, a first URB694 derivative, URB937, (16, Fig. (5) , IC 50 = 26.8 nM) was disclosed to selectively inhibit FAAH in the periphery [81] .
In addition, O-phenylcarbamates were also described by Astellas (17, Due to their properties towards FAAH, carbamate-based inhibitors were also largely investigated by Sanofi-Aventis. Numerous series were described, based on various O-and Nsubstituents including alkyl, piperazinyl, azetidinyl or thioazolyl, as illustrated in Fig. (7) [84] [85] [86] [87] [88] [89] [90] [91] . These inhibitors were all described for having an analgesic activity and their inhibition potencies against mFAAH are summarized in Fig. (8) .
Two other carbamate-based families were developed at Sigma-Tau Pharmaceuticals: one is based on an enol carbamate template (27 and 28, Fig. (9) , IC 50 and K i both < 10 nM, mFAAH) [92] , and the other is based on an oxime carbamate (29, Fig. (9) , IC 50 and K i both < 10 nM, mFAAH) [93] . These compounds are described as selective for FAAH over various cannabinoid-related targets (< 60 % versus CB 1 , CB 2 , TRPV1, NAPE-PLD, AMT, DAGL, MAGL, at a concentration equal to 1000-fold their IC 50 against FAAH).
Interestingly, 27-29 inhibit FAAH in a reversible manner which is quite unexpected for carbamate-type inhibitors. Invivo, compound 28 exhibits analgesic activity and reduces anxiety without affecting locomotor activity, whereas 29 was able to reduce anxiety as well as the hyperalgesia in a model of neuropathic pain. 
II.3.3. Urea-based FAAH Inhibitors
Due to its high resistance towards chemical and biological hydrolysis, the urea function is usually not considered as a pharmacophore to inhibit serine hydrolases. However, it was shown that adding a good leaving group, such as an aniline function, transforms urea into a more reactive moiety, which could then function as enzyme inhibitor. Urea-based FAAH inhibitors originated from high-throughput screening studies of industrial chemical libraries. Both Janssen Pharmaceuticals and Takeda companies described compounds based on a piperazinyl urea moiety (30 and 31, Fig. (12) ). Compound 30 exhibits an IC 50 value of 16 nM or 50 nM depending on the source of enzyme (human and rat, respectively) [94] , while for 31 100 % of enzyme (rFAAH) inhibition was obtained at 1 M [95] .
However, the development of urea-based FAAH inhibitors really started with the discovery at Pfizer of PF-622 and PF-750 (32 and 33, Fig. ( Indeed, after a high-throughput screening study to improve either drug-like pharmacokinetic properties and/or selectivity, Pfizer published a new kind of mechanistic class of inhibitors, based on the piperidinyl urea scaffold, showing a combination of potency and excellent selectivity [58] . Of note, the development of this class of inhibitors at Pfizer beneficiated from a h/rFAAH three dimensional structure [46] . Thus, the stable acyl-enzyme complex was identified by MALDI-MS analyses and then by X-ray structures with h/rFAAH, which confirmed the addition of the inhibitor to the active serine and the irreversible mechanism of inhibition. These studies led to a new chemical family obtained by replacing, not only the quinoline group of 32 and 33 with a biaryl ether group, but also the aniline leaving group with a 3-aminopyridine one. These changes resulted in the inhibitor PF-3845 (34, Fig. (10) ) which possesses much higher activity (k inact /K i = 14,310 M 1 .s -1 ) [47] . Pfizer further described in several patents the synthesis and pharmacological evaluations of numerous urea-based inhibitors (e.g. compounds 35-40, Fig. (10) ) [96] [97] [98] [99] [100] . One line of research was to design more rigid compounds using a methylenepiperidine scaffold while incorporating a polar moiety to improve the pharmacokinetic parameters. This led to the clinical candidate PF-04457845 (35, Fig. (10) , k inact /K i = 40,300 M -1 .s -1 ) which contains a pyridazinyl moiety instead of the 3-aminopyridine one. This inhibitor exhibits a high selectivity for FAAH, excellent potency and good pharmacokinetic profile. The same company also prepared a new series of rigid piperidines where the methylene group was replaced with a C4-spirocycle (41 and 42, Fig. (10) ) [101, 102] . The later inhibitors possess, similarly to the inhibitors containing a methylene unit, a high potency against FAAH activity.
It is difficult to directly compare the inhibitory activity of Pfizer's ureas with the other types of inhibitors since their potency is expressed in the literature as k inact /K i values instead of the IC 50 values traditionally reported. However, the use of k inact /K i values appears more suitable than IC 50 values when studying irreversible inhibitors. Note that in the same assay, the well-known URB597 (10, KDS-4103, Fig. (5) ) shows a k inact /K i value of 1,590 M -1 .s -1 Fig. (11) . Based on all the reported assays, piperidinyl ureas appeared to be more selective and efficacious than KDS-4103 [47] . Fig. (11) . Potency of Pfizer's ureas compared to the carbamatebased inhibitor KDS-4103 (10, Fig. (5) ). Note that a highly potent inhibitor is characterized by a high k inact /K i value (and a low IC 50 value).
While other urea-derivatives have been investigated by several pharmaceutical companies, piperazinyl urea remains the most common template. i) Sanofi-Aventis described two compounds exhibiting dual inhibition against both mFAAH and mMAGL (43 and 44, Fig. (12) ) [103, 104] . ii) Janssen Pharmaceuticals reported two additional series of compounds (45-49, Fig. (12) and 53, Fig. (13) ). Compound 46 (Fig. (12) , IC 50 = 19 nM and 6 nM on hFAAH and rFAAH) [105] is derived directly from JNJ-1661010 (45, Fig (12) ) structure, whereas compounds 47-49 [106] contained a biaryl ether motif. When administered in-vivo, 47 (Fig. (12) , IC 50 = 8 nM and 10 nM on hFAAH and rFAAH, 20 mg/kg, po) showed analgesic effects in a model of mechanical allodynia. Its activity was improved by replacing the benzisoxazole moiety with an isoxazolopyridine resulting in compound 48 described as a subnanomolar inhibitor [107] . Inspired from the structure of 48, 49 (Fig. (12) , IC 50 = 1 nM) conserves a biaryl ether moiety, but a pyridine replaces the isoxazolopyridine motif [108] . iii) Other piperazinyl urea-based FAAH inhibitors were shown to possess in-vivo efficacy. For instance, Astella published a series of inhibitors, illustrated with 50 ( Fig. (12) , IC 50 = 160 pM, rFAAH), which seem to be useful in the context of overactive bladder [109] , and Takeda published two families of compounds based on an isoxazole or pyridine moiety, exemplified here with 51, which exhibited analgesic effect at 10 mg/kg [110] , and 52, which was proposed to treat sleep disorders [111] . iv) More recently, azetidinyl ureas were described as FAAH inhibitors. Vernalis described compound 53 Fig. (13) which exhibits an IC 50 value of 3 nM on hFAAH [112] . Janssen Pharmaceuticals investigated also azetidinyl ureas with compound 54 Fig. (13) , which presents an IC 50 value of 1 nM both on hFAAH and rFAAH [113] , and the recently published rigid spirocyclic compound 55 (Fig. (13) , 10 nM and 20 nM on hFAAH and rFAAH, respectively) [114] .
II.3.4. Boronic acid-based FAAH Inhibitors
Recently, a new kind of FAAH inhibitors using a boronic acid as the electrophilic function was reported. This function has been already described for inhibiting serine proteases in a reversible manner [115] . Indeed, boron's ability to go up from a trigonal planar geometry to a tetrahedral geometry allows boronic acids to form a transient and reversible tetrahedral intermediate with the nucleophilic serine. Both Infinity Pharmaceuticals (56, Fig. (14) ) [116] and Minkkila and co-workers (57, Fig. (14) ) [117] published in 2008, the first arylboronic acids described as FAAH inhibitors. These two inhibitors exhibited nanomolar activities (K i 10 nM for 56 and IC 50 = 9.1 nM for 57) and a reversible inhibition of the enzyme. In the case of compound 56, kinetic data consolidated the hypothesis of a reversible inhibition. Furthermore, supplementary investigations were undertaken to unravel the interactions between the inhibitor and the enzyme. Both the molecular modelling studies and mutagenesis studies of rFAAH demonstrated that the phenyl moiety of these inhibitors interacts with the enzyme's hydrophobic channel.
Infinity Pharmaceuticals further covered this area with three patents in 2009 and 2010. Thus, they developed several series of FAAH inhibitors based on various substituted arylboronic acids, exemplified with compounds 58 [118] and 59 [119] (Fig. (14) , K i 10 nM), and also based on a tetrahydro pyridine boronic acid (i.e compound 60, Fig. (14) , K i 10 nM) [120] .
II.3.5. FAAH Inhibitors of Miscellaneous Structures
Whereas initially, carbamate and activated ketone-based inhibitors were mainly described, a wider diversity of templates has been explored since 2006. Some indole and pyrrole derivatives were investigated by Ironwood Pharmaceuticals (Microbia) which published several patents from 2006 to 2011 [121] [122] [123] [124] [125] . Therein, different series of compounds were disclosed that were, not only FAAH inhibitors, but that also interact with one or several targets involved in inflammation and pain (e.g. COX-1 or COX-2). For example, compounds 61 [122] , 62 [123] and 63 [125] (Fig. (15) ) were found to inhibit hFAAH at submicromolar concentrations.
Bial (Portela & C o ) reported several series of oxadiazolones (64, 65 and 66, Fig. (16) ) as FAAH inhibitors being selective for peripheral over CNS located FAAH [126] [127] [128] .
Indeed, following administration of the inhibitors to mice (30 mg/kg, p.o.) the residual activity in liver was found to be very low (5 %, 6 % and 29 % compared to the control, for 64, 65 and 66 respectively) whereas it was almost completely conserved in brain (83 %, 86 % and 84 % compared to the control, for 64, 65 and 66 respectively).
Merck designed various heterocycle-based FAAH inhibitors like imidazole, pyrazole or oxazole cycles. Thus, two series of imidazole derivatives were described which inhibit hFAAH with nanomolar and subnanomolar activities (Fig.  (17) , compounds 67 and 68, IC 50 values of 6.3 nM and 0.2 nM, respectively) [129, 130] . In addition, a pyrazole series was published, illustrated with 69 ( Fig. (17) , IC 50 value of 0.47 nM) [131] and also an oxazole one, represented by 70 Fig. (17) [132] . The inventors described the later inhibitor as having good cell permeability (IC 50 = 5 and 20 nM, in cell lysate and in whole cell, respectively).
Renovis published several lipophilic and polycyclic compounds as FAAH modulators. For instance, compounds 71 [133] and 72 [134] exhibited nanomolar IC 50 values (Fig.  (18) , IC 50 < 100 nM and IC 50 = 1.2 nM for 71 and 72, respectively) while compound 73 (Fig. (18) ) [135] showed more than 75 % of FAAH inhibition at 1 M compared to the control.
Janssen Pharmaceuticals developed also a family of inhibitors based on a pyrimidine moiety with a C6 aryl group and a C4 amine function. Compounds 74 [136] and 75 Fig.  (19) [137] featured nanomolar activities (Fig. (19) , IC 50 = 1 and 3 nM for 74 and IC 50 = 7 and 240 nM for 75, against hFAAH and rFAAH, respectively).
Very recently, Infinity Pharmaceuticals identified the isoxazoline heterocycle as a new template for FAAH inhibition. Four series of compounds were presented based on this new scaffold. The representative compounds 76, 77, 78 and 79 ( Fig. (20) ) were reported to have K i 100 nM and an irreversible mode of hFAAH inhibition [138] [139] [140] . Indeed, the authors reported evidence for a covalent FAAH inhibition via kinetic data, on one hand, and rapid dilution experiments, on the other hand, confirming the irreversible or slowly reversible inhibition. This mechanism of action was explained by the nucleophilic addition of the active Ser-241 on the isoxazoline C=N function followed by the elimination of the leaving group, i.e. Br or ArO substituent at C3.
II.3.6 Other Structures Not Covered by Patents
Since 2006, a number of inhibitors have been published in the literature but are not covered by patents. We have summarized here the main families. A family of 2-thioxo- Fig. (19) . Pyrimidine-based FAAH inhibitors from Janssen Pharmaceuticals. Fig. (20) . Isoxazoline-based FAAH inhibitors described by Infinity Pharmaceuticals.
imidazolidin-4-ones was described to inhibit FAAH in a reversible and competitive manner (80, Fig. (21) , pI 50 = 5.86) [141] . Then, benzothiazole-based inhibitors were reported to reversibly inhibit FAAH with nanomolar activity (81, Fig.  (21) , IC 50 = 1.7 nM) [142] . During the same year, two distinct series of paracetamol [143] and ibuprofen [144] analogues were disclosed to block FAAH activity with good to moderate potency (82 and 83, Fig. (21) , IC 50 = 100 nM and pI 50 = 5.86, respectively). A unique series of 1-indol-1-ylpropan-2-ones was also described for a dual inhibition towards FAAH and cytosolic phospholipase A 2 (84, Fig. (21) , IC 50 = 47 nM and 2.2 M against FAAH and cPLA 2 , respectively) [145] . In 2009, -lactam-based inhibitors were disclosed to inhibit FAAH in a reversible manner without being processed by the nucleophilic serine (85, Fig. (21) , IC 50 = 8 nM) [51, 146] . Additionally, the first potent noncovalent and competitive inhibitors of FAAH were disclosed (86, Fig. (21) , IC 50 = 36nM) [147] .
II.4. Current Clinical Trials Involving FAAH Inhibitors
Based on the preclinical studies reported so far, the most promising therapeutic applications for FAAH inhibitors are to be found in the treatment of pain and mood, and sleep disorders. Recently, Pfizer undertook a phase II clinical trial with PF-04457845 (35, Fig. (10) ) to evaluate its efficacy, safety and tolerability in knee osteoarthritis (NCT00981357). Another small scale clinical trial (NCT01092845) aimed at studying the effect of 35 on sleep. Indeed, a positive effect on sleep would represent a proof-of-concept for the CNS efficacy of the compound, and more largely of increasing AEA levels, in humans.
In addition, phase II clinical trials were also undertaken to evaluate SSR-411298, a FAAH inhibitor developed by Sanofi-Aventis, for treatment of major depressive disorders in the elderly patients (NCT00822744). To date, neither the inhibitor structure nor results were reported concerning these investigations. Note however that although the development of SSR-411298 in this indication has been abandoned, other indications (e.g. pain, NCT01439919) are being investigated.
Infinity Pharmaceuticals is developing IPI-940 (no structure available) in order to treat various types of pain. Phase I resulted in positive data, and IPI-940 is presented as a welltolerated compound with good pharmacokinetic, pharmacodynamic and safety properties. Purdue Pharmaceutical Products is expected to initiate Phase II studies with this compound. Finally, Vernalis has its own FAAH inhibitor, V158866 (IC 50 = 24 nM) entering Phase I clinical trials.
We are at the early stages of the clinical development of FAAH inhibitors; the results of the first Phase II trials are eagerly awaited to determine whether FAAH inhibition will prove to be a viable drug target.
III. MONOACYLGLYCEROL LIPASE
III. 1. MAGL, Structure and Mechanism of Action
Although the existence of a monoacylglyceride hydrolase in the adipose tissues was reported decades ago [148, 149] , MAGL became more actively investigated after its role in controlling 2-AG (Fig. (22) ) levels was demonstrated [3] [4] . [150] , MAGL activity is governed by the classical Ser-His-Asp catalytic triad of the serine hydrolases. Additionally, four cysteine residues were shown to interact with some enzyme inhibitors [151] [152] [153] . Thus for instance, N-arachidonoylmaleimide, disulfiram and octhilinone were developed as MAGL inhibitors targeting those cysteine residues [151, 153, 154] .
Very recently, the hMAGL's three dimensional structure was independently elucidated by two research teams, with a resolution of 2.2 Å [155] and 2.7 Å [156] , respectively. The publication by Sanofi-Aventis described also a co-crystal between MAGL and SAR-629, one of their own MAGL inhibitors (87, Fig. (23) ). In silico modelling of the tetrahedral intermediate between 2-AG and the active serine [155, 156] , as well as the X-ray structure of MAGL-SAR-629 co-crystal [156] , allowed important structural features to be established. i) At the surface of the enzyme, a large highly hydrophobic cavity which leads to the active site is present. This channel, made of several hydrophobic residues, apears to be suitable for interacting with the lipophilic chain of the substrate and seems to govern substrate specificity. ii) a lid (or cap) is present at the entrance of the channel. This lid is suggested to allow MAGL to interact with the cell membrane, thus helping in recruiting its lipophilic substrates from the membrane. Note that MAGL is found in both soluble and particulate fractions suggesting that the interaction between the lid and the membrane is reversible. iii) Closer to the active site a hydrophilic pocket is present and appears to be able to accommodate the substrate's glycerol moiety. This pocket, named "alcohol-binding pocket" [155] or "exit-hole" [156] by the two groups, contains three residues Ala51 (Ala61 in Sanofi's paper), His121 (His131) and Tyr194 (Tyr204), important for substrate recognition, and thus potential residues to be targeted by novel inhibitors. iv) Two non-catalytic cysteines, Cys201 (Cys211) and Cys242 (Cys252), which are supposed to be targeted by Michaelacceptor inhibitors, are in the vicinity of the catalytic site. Cys242 (Cys252) lies very close to the active Ser, deeply buried in the catalytic pocket, and Cys201 (Cys211) is farther from the active serine but remains accessible to inhibitors from the active site. On the contrary, Cys208 (Cys218) is described as pointing toward the outside of the enzyme. It is expected that these crystal structures will aid the development of novel MAGL inhibitors.
III.2. Pharmacology of 2-AG or why Inhibiting MAGL Hydrolase Activity?
2-AG is present at high levels in the brain, where it exerts an important role in controlling neurotransmitters release, and is also present in the periphery throughout the organism. (For a review see [157] ) Indeed, beside its role as transmitter, 2-AG is an intermediate in lipid metabolism and, very likely, only a limited fraction of the 2-AG available acts as lipid mediator. Among the proposed roles for 2-AG, it was demonstrated to be involved in various processes like neuroprotection [158] [159] [160] , appetite [161] , cognitive and affective behaviours, or nociception [162] and inflammation, resulting from CNS and peripheral system locations, respectively. (for a complete review, see [157] ) Furthermore, several studies demonstrated the involvement of 2-AG in controlling cell proliferation and invasion, suggesting that MAGL inhibitors could be relevant in cancer treatment [163, 164] . Preclinical studies suggested that MAGL inhibition could represent an interesting strategy for treating pain [20, 36, 165, 166, 167] ,   Fig. (21) . FAAH inhibitors not covered by the patents. inflammation [37, 166, 168] , vomiting, nausea [169] and anxiety [40] . Investigations for MAGL inhibitors are more recent that those on FAAH, resulting in a limited number of inhibitors (see [54, 170] ). Below we will review the available patents describing MAGL inhibitors.
III.3. MAGL Inhibitors
III.3.1. Urea-based MAGL Inhibitors
Sanofi-Aventis was the first pharmaceutical company which published MAGL inhibitors. Urea-based compounds bearing piperazinyl and triazole or triazolopyridine moieties as substituents were designed and developed.
Compounds 88 [104] , 89 [171] and 90 [103] (Fig. (23) ) were found to inhibit mMAGL at nanomolar concentrations (IC 50 values of 4 nM, 4 nM and 2 nM for 88, 89 and 90, respectively) and to exhibit either selectivity for MAGL over FAAH, or dual nanomolar inhibition of both enzymes. Makriyannis' group at Northearsten University also disclosed several urea-based MAGL inhibitors such as 91 (IC 50 = 42 nM against hMAGL) [172] . Note that, due to its isothiocyanate function, this compound could be useful as a covalent probe to explore MAGL properties, and notably the cysteine residues.
III.3.2. Carbamate-based MAGL Inhibitors
Piomelli's group reported the ability of a carbamate derivative, URB602 (92, Fig. (24) ), to inhibit MAGL (IC 50 value of 28 M) [173] . However, this compound lacks selectivity since it inhibits FAAH with a similar potency [174, 175] .
Much more recently, by screening its own library of carbamates, Cravatt's group found piperidinyl and piperazinyl carbamates which were able to inhibit MAGL without affecting FAAH activity [176] . The authors demonstrated that an increased steric hindrance improved the selectivity toward MAGL. This work resulted in the design of a selective and potent MAGL inhibitor with the synthesis of compound JZL184 ((93, Fig. (24) ) [177, 178] . Indeed, with the incorporation of two oxygen atoms in the 3 and 4 positions of the phenyl rings, they obtained an excellent selectivity in the range of 400-fold (IC 50 values of 10 nM and 4690 nM for MAGL and FAAH, respectively). In addition, inspired by the selective piperazinyl urea-based FAAH inhibitor 32 (PF-622, Fig. (10) ) and by 93, Cravatt et al. developed a series of compounds, such as 94 (JZL195, Fig. (24) ), which inhibited FAAH and MAGL with a similar potency without affecting other serine hydrolases (IC 50 values of 13 and 19 nM for FAAH and MAGL, respectively) [9] .
Today, compound 93 is extensively used as a reference pharmacological tool to study the effects of MAGL inhibition. Several publications report the use of 93 for increasing 2-AG levels and the resulting effects, for instance, in cancer pathogenesis [164] , neuropathic pain [36] , anxiety [40] and colon inflammation [168] .
III.3.3. MAGL Inhibitors of Miscellaneous Structure
MAGL inhibitors based on an activated ketone were described by Makriyannis' group at Northeastern University. The -keto oxadiazole derivatives, such as 97, are quite active against MAGL, although they remain more active against FAAH (Fig. (25) , IC 50 = 71 nM and K i = 17 nM against hFAAH) [179] .
Janssen Pharmaceuticals published a series of three patents describing MAGL inhibitors based on an amide function. Each patent is illustrated with a lead compound (98-100, Fig. (25) ) that inhibit MAGL with an IC 50 value of 10.4 nM, 10 nM and 50 nM, respectively) which was tested in various in-vitro and/or in-vivo pharmacological evaluations [180] [181] [182] . Thus for instance, 98 was able to increase 2-AG levels in an ex-vivo preparation of rat brain. In-vivo, compound 98 (30 mg/kg, po) completely prevented the CFA-induced heat hypersensitivity and partially the CFAinduced pressure hypersensitivity. Compound 99 was similarly tested in various experimental models to assess its antinociceptive properties. The group also published crystal structures of different MAGL mutants and co-crystallised forms with compounds 99 and 100 with resolutions of 1.35 and 2.3 Å, respectively [183, 184] . 
III.3.4. Other Recent Structures Not Covered by Patents
A -lactone inspired from the serine hydrolase inhibitor, tetrahydrolipstatin, was designed by Di Marzo's group. OMDM169 (95, Fig. (25) ) inhibits hMAGL with an IC 50 value of 0.89 M in a competitive manner. However, the authors also disclosed that compound 95 also inhibits rFAAH with an IC 50 value of 3.0 M [165] . Also of interest, is the finding that the 5-methoxy-1,3,4-oxadiazol-2(3H)-one moiety (96, Fig. (25) ) is also able to inhibit MAGL activity, thus offering an additional template for the development of inhibitors of the enzyme [185, 186] .
IV. N-ACYLETHANOLAMINE ACID AMIDASE
IV.1. NAAA, Structure and Mechanism
Like FAAH, the N-Acylethanolamine-hydrolyzing Acid Amidase (NAAA) is also able to cleave amide bonds of saturated and unsaturated NAEs [8] . NAAA is thought to exert almost all of its hydrolytic activity towards PEA (Fig. (2) ) since other NAEs are hydrolysed at much lower rates [187] . Moreover, it is notable that NAAA does not hydrolyse 2-AG. Although NAAA, like FAAH, exerts its activity towards NAEs, there is no sequence homology between these two enzymes, and whereas the optimum pH for FAAH activity is around 9, NAAA's activity is the highest at pH 5 [188, 189] . This is actually consistent with the subcellular localisation of NAAA in the lysosomes [189, 190] . Moreover, NAAA shares high sequence homology with the human acid ceramidase family, and its mode of action and structural features are closer to those of this hydrolase family than to FAAH [191] . For instance, similarly to what is found for the choloylglycine hydrolase superfamily [192] , and more precisely for the acid ceramidase family, the precursor form of NAAA is auto-catalytically cleaved into two subunits, and , at acidic pH. Then, this cleavage leads to the appearance of the unmasked N-terminal nucleophilic residue responsible for the catalytic activity of NAAA [193] . Wang et al. also identified Cys126 as the N-terminal residue and Cys126/ Arg142/Asp154 as the residues constituting the catalytic triad of the human NAAA. As a consequence, the strategy for NAAA targeting is mainly based on the cysteine hydrolase activity of the enzyme, contrasting to the strategies used to target the serine hydrolases of the endocannabinoid system (i.e. FAAH, MAGL, and ABHD6). Because the discovery and initial characterisation of NAAA are quite recent, only a very limited number of studies have been published to date.
IV.2. Pharmacology of PEA or why Inhibiting NAAA Hydrolase Activity?
Several studies suggested that the role of NAAA is to regulate NAEs levels in macrophages and peripheral tissues [194] . As PEA is NAAA's primary substrate, its inhibition appears to be a relevant alternative to FAAH inhibition in the induction of anti-inflammatory [195] , analgesic [27, 28] and neuroprotective effects [196] . Indeed, these effects can be mediated by PEA through receptors that are distinct from cannabinoid receptors (e.g. PPAR ) [197] . Fig. (26) ) of palmitic acid were developed [198] [199] [200] [201] .
Compounds 101, 102 and 103 were tested against rFAAH and rNAAA (solubilised from the 12000*g pellet of rat lung homogenates) and were found to be selective at 100 M for NAAA versus FAAH (84, 71 and 77 % of NAAA inhibition versus 36, 0 and 8 % of FAAH inhibition, for compounds 101, 102 and 103 respectively) [198, 199] . Similarly, compounds 104 and 105 do not inhibit FAAH at 100 M. The inhibition mechanism of 104 was further investigated and 104 was found to act by a reversible and noncompetitive mechanism. This compound was also shown to inhibit NAAA in intact macrophages and in macrophage homogenates [200] .
More recently, another study based on PEA analogues has been published. The authors used recombinant rNAAA expressed in HEK cells to test novel series of NAAA inhibitors. Among the assayed compounds, 106 (Fig. (26) ) was found to be a selective and competitive NAAA inhibitor [201] .
IV.3.2. -lactone-based Inhibitors
To date, and to our knowledge, the only inhibitors known for inhibiting NAAA with a sub-micromolar activity are based on the -lactone template.
Compounds 107 and 108 (Fig. (27) ) [202] were found to inhibit rNAAA (recombinant HEK cells expressing rNAAA) in a non-competitive and reversible manner with IC 50 values of 115 and 420 nM, respectively. As no crystal structure of NAAA is available, the authors built a model of NAAA catalytic site based on its high homology with conjugated bile acid hydrolase (CBAH). This model, which was validated by the docking of the tetrahedral intermediate between PEA and Cys131 (rNAAA), is to date, the only tool available for designing new inhibitors of NAAA [203] . Compound 107 [204] as well as compound 108 [202] exhibited antiinflammatory effects in various inflammation models where URB597 (KDS-4103 or 10, Fig. (5) ) had no effect, suggesting that NAAA is solely implicated.
V. CURRENT AND FUTURE DEVELOPMENTS
When looking at the variety of compounds described here, it is safe to say that we now have the tools to fully explore the consequences of FAAH and MAGL selective inhibition. The early thinking was that using an inhibitor would allow to increase local levels of endocannabinoids due to their on-demand production. However, it appears that the administration of a FAAH or MAGL inhibitor results in increased endocannabinoid levels throughout the body (see for instance [205, 206] ). Although this results in a situation not that different from agonist administration, advantages of inhibiting the endocannabinoid hydrolysing enzymes still exist. First, by selectively inhibiting FAAH or MAGL only a subset of the effects obtained following agonists administration are observed. Thus when looking at the cannabinoid tetrad of effects [23] -i.e. antinociception, catalepsy, hypolocomotion, hypothermia -all the effects are present following CB 1 agonist administration, but only antinociception is induced upon FAAH inhibition. Another interesting point is that neither selective FAAH inhibition nor selective MAGL inhibition induce a cataleptic behaviour in mice. However, upon blockade of both enzymes catalepsy is present, as it is following CB 1 agonist administration ( Table 1 , and see [9] ). Fig. (26) . Substrate-based NAAA inhibitors. Based on the published studies, it appears that FAAH inhibition generates less CNS-related side effects compared to MAGL inhibition. Thus for instance MAGL, but not FAAH, inhibition reduces locomotion. Another difference between MAGL and FAAH inactivation is the adaptations in CB 1 signalling observed following MAGL, but not FAAH, complete and chronic inhibition [207, 208] . These adaptations, resulting in functional antagonism of the endocannabinoid system, provoke a lower analgesic effect upon MAGL chronic inhibition compared to FAAH inhibition, even though acute MAGL inhibition induces similar effects than acute FAAH inhibition [208] . Based on these studies, it has been suggested, but has not been demonstrated yet, that partial blockade of MAGL could preserve its analgesic potential also during chronic administration.
It is also worth noting, that FAAH inhibition seems to be safe although a large number of bioactive lipids, besides NAEs, are hydrolysed by the enzyme. For instance, chronic inhibition of FAAH increases NAE levels, but also Nacyltaurines which are transient receptor potential channels agonists [206] . Conversely, brain levels of the GPR18 receptor endogenous agonist N-arachidonoylglycine are decreased following FAAH inhibition. [19] The question whether MAGL inhibition results in the exclusive modulation of monoacylglycerols (and corresponding fatty acids) [178, 205] remains open. Of great interest is the recent demonstration that MAGL-produced arachidonic acid is further metabolized in prostaglandins. Thus inhibition of MAGL results in increased levels of 2-AG, but also in decreased prostaglandins levels, further supporting MAGL as an interesting anti-inflammatory target [209] .
Because
NAEs (e.g. anandamide and Npalmitoylethanolamine) and 2-AG levels are profoundly affected throughout the body by FAAH and MAGL, respectively, inhibition, one could question the interest in pursuing inhibitors of the additional endocannabinoid hydrolysing enzymes (NAAA, ABHD6, ABHD12). One argument in favour of these enzymes can be found in the localisation of specific enzymes at the tissue and cell level. This results in enzymes controlling pools of signalling mediator. Thus, although MAGL controls 85 % of 2-AG hydrolysis in whole brain homogenates, ABHD6 selective inhibition [210] [211] [212] in intact neurons and in brain slices results in increased 2-AG levels and 2-AG induced-synaptic plasticity, respectively [7] . Note that it was also recently demonstrated that carboxylesterase-1 (CES-1) participates in the control of 2-AG metabolisms in macrophages [213] . When looking at NAAA, its inhibition in intact macrophages reduces AEA degradation to a similar, if not higher, extent than FAAH inhibition [202, 214] . These two examples underscore the potential of targeting NAAA, ABHD6, and perhaps ABHD12, to more precisely fine-tune endocannabinoid levels in a subset of cells inside a tissue. Thus, in addition to advancing the development of FAAH and MAGL inhibitors from bench to bedside, efforts aiming at inhibiting the other endocannabinoid-hydrolyzing enzymes should bring exciting new developments in the endocannabinoid field.
